Pioneering iPSC-Derived Cell Therapy & Regenerative Medicine
At Ricoh Biosciences, we leverage our proprietary iPSC differentiation technology to develop high-quality, functional cells for regenerative medicine and cell therapy applications. Our expertise in transcription factor-based differentiation allows us to rapidly generate clinically relevant cell types with high reproducibility, providing a scalable foundation for next-generation therapies.
Our Approach
We focus on advancing iPSC-derived cell therapies by:
- Developing high-quality, functional cell types for therapeutic use
- Optimizing differentiation protocols for clinical translation
- Establishing scalable manufacturing to meet regulatory and commercial requirements
Pipeline: iPSC-Derived Cell Therapy & Regenerative Medicine
| Indication | iPSC-Derived Cell Type | IND | Phase 1 | Phase 2 | Phase 3 | Approval | |
|---|---|---|---|---|---|---|---|
| Parkinson's Disease (PD) | Dopaminergic Neurons | ||||||
| Alzheimer's Disease (AD) | Excitatory Neurons Microglia | | |||||
| Amyotrophic Lateral Sclerosis (ALS) | Motor Neurons | ||||||
| Multiple Sclerosis (MS) | Oligodendrocytes | ||||||
| Cancer | T-Cells |
Partnership Opportunities
We collaborate with partners to advance iPSC-derived therapies. Our flexible engagement model provides them with:
- Access to our proprietary iPSC differentiation technology
- Opportunities to co-develop cell therapies for clinical applications
- Scalable cell manufacturing capabilities to support clinical translation
Join Us in Advancing Regenerative Medicine
Ricoh Biosciences is committed to accelerating the development of iPSC-derived therapies. We welcome partnerships to bring transformative treatments to patients.
How Can We Help?
"*" indicates required fields
Contact Us
Have a question about our products, services, or custom projects? Our team is here to help—reach out and we’ll get back to you as soon as possible.
Subscribe
By signing up you are agreeing to our Privacy Policy